Periodic Oxaliplatin Administration in Synergy with PER2‐Mediated PCNA Transcription Repression Promotes Chronochemotherapeutic Efficacy of OSCC

Developing chemotherapeutic resistance affects clinical outcomes of oxaliplatin treatment on various types of cancer. Thus, it is imperative to explore alternative therapeutic strategies to improve the efficacy of oxaliplatin. Here, it is shown that circadian regulator period 2 (PER2) can potentiate...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Qingming, Xie, Mengru, Yu, Shaoling, Zhou, Xin, Xie, Yanling, Chen, Guangjin, Guo, Fengyuan, Chen, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839751/
https://www.ncbi.nlm.nih.gov/pubmed/31728273
http://dx.doi.org/10.1002/advs.201900667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839751/
https://www.ncbi.nlm.nih.gov/pubmed/31728273
http://dx.doi.org/10.1002/advs.201900667

Ejemplares similares